- R&D Network
-
Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.
R&D Network
Hanmi R&D network consists of 6 sites creating a synergistic effect. Fully integrated 3 R&D Centers in Dongtan (Korea), Paltan (Korea), and Beijing (China) focus on new drug discovery and formulation research. Seoul R&D Center in our headquarters performs clinical research, regulatory affairs and licensing business. In addition, there are two process development research sites for biologics and chemical APIs.
Hanmi R&D Center
Seoul R&D Center (Headquarters)
Pharmaceutical R&D Center
Bioprocess Research Center
Hanmi Fine Chemical
Central Research Institute
NAME | Location | Major Fields of Research | Number of Personnel |
---|---|---|---|
Hanmi R&D Center | Dongtan, Gyeonggi-do in Korea | New biological drugs, New chemical drugs | 150+ |
Seoul R&D Center (Headquarters) | Songpa-gu, Seoul in Korea | Clinical studies, Regulatory affairs, Licensing in & out | 110+ |
Pharmaceutical R&D Center | Paltan, Gyeonggi-do in Korea | New medicines, Drug transfer platform technology | 60+ |
Bioprocess Research Center | Pyeongtaek, Gyeonggi-do in Korea | Manufacturing and development of recombinant protein products | 50+ |
Hanmi Fine Chemical Central Research Institute | Sihwa, Gyeonggi-do in Korea | Mass production of active pharmaceutical ingredients | 50+ |
Beijing Hanmi Research Center | Beijing in China | New bispecific antibodies | 120+ |